Display options
Cite
Chen R, Peng PC, Wen B, et al. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016;9(1):32-40doi: 10.1016/j.tranon.2015.11.010.
Chen, R., Peng, P. C., Wen, B., Li, F. Y., Xie, S., Chen, G., Lu, J., Peng, Z., Tang, S. B., Liang, Y. M., & Deng, X. (2016). Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Translational oncology, 9(1), 32-40. https://doi.org/10.1016/j.tranon.2015.11.010
Chen, Ran, et al. "Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis." Translational oncology vol. 9,1 (2016): 32-40. doi: https://doi.org/10.1016/j.tranon.2015.11.010
Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010. PMID: 26947879; PMCID: PMC4800062.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010.

Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.

Translational oncology

Ran Chen, Pei-Chun Peng, Bin Wen, Fu-Ying Li, Sheng Xie, Guozhong Chen, Jiefu Lu, Zhuoyu Peng, Shao-Bo Tang, Yu-Mei Liang, Xin Deng

Affiliations

  1. The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530011, China.
  2. Ruikang Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
  3. The first people's hospital of Nanning, Nanning, 530022, China.
  4. Ruikang Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China. Electronic address: [email protected].

PMID: 26947879 PMCID: PMC4800062 DOI: 10.1016/j.tranon.2015.11.010

Abstract

This systematic review and meta-analysis evaluated anti-programmed cell death (PD)-1 immunotherapy (nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy or other conventional drugs in the treatment of malignant tumors. We searched the following databases, PubMed, Medline, Embase, Cochrane, Wangfang Data, Weipu, and China National Knowledge Infrastructure, and the reference lists of the selected articles for randomized controlled trials (RCTs) of anti-PD-1 therapies in humans. The outcome measures were overall survival, treatment response, and adverse events. Only four randomized controlled trials met our inclusion criteria. Three of these evaluated responses to nivolumab, whereas one tested pembrolizumab. The result of our analysis suggested that nivolumab may improve the overall response rate in treating melanoma relative to chemotherapy and has few associated adverse events. Similarly, in metastatic melanoma patients, nivolumab had a significant advantage over dacarbazine in terms of 1-year survival, progression-free survival, and objective response rate. Regarding dose levels of nivolumab for patients with metastatic renal cell carcinoma, the outcomes in response to 2 and 10 mg/kg were similar, but both had significant advantages over 0.3 mg/kg. In addition, pembrolizumab showed similar outcomes in response to 2- and 10-mg/kg treatment. Anti-PD-1 immunotherapy appears to be safe and effective for patients with melanoma or metastatic renal cell carcinoma. Our meta-analysis is limited, but additional clinical trials are warranted to verify this preliminary evidence of positive outcomes and before anti-PD-1 therapy can be recommended for routine clinical use.

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Cancer Res. 2003 Nov 1;63(21):7462-7 - PubMed
  2. Lancet. 2014 Sep 20;384(9948):1109-17 - PubMed
  3. Curr Oncol Rep. 2013 Apr;15(2):98-104 - PubMed
  4. Int J Cancer. 2006 Jul 15;119(2):317-27 - PubMed
  5. Trends Immunol. 2006 Apr;27(4):195-201 - PubMed
  6. PLoS One. 2013 Dec 11;8(12):e82870 - PubMed
  7. J Clin Oncol. 2015 May 1;33(13):1430-7 - PubMed
  8. Hematol Oncol Stem Cell Ther. 2014 Mar;7(1):1-17 - PubMed
  9. Blood. 2008 Dec 1;112(12):4371-83 - PubMed
  10. N Engl J Med. 2015 Jan 22;372(4):320-30 - PubMed
  11. J Immunol. 2003 Feb 1;170(3):1257-66 - PubMed
  12. Nat Immunol. 2001 Mar;2(3):261-8 - PubMed
  13. Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4607-13 - PubMed
  14. Annu Rev Immunol. 2008;26:677-704 - PubMed
  15. Neuro Oncol. 2009 Dec;11(6):757-66 - PubMed
  16. J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10 - PubMed
  17. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33 - PubMed
  18. Blood Rev. 2015 Jan;29(1):25-32 - PubMed
  19. J Urol. 2008 May;179(5):1954-9; discussion 1959-60 - PubMed
  20. Br J Cancer. 2013 Apr 30;108(8):1560-5 - PubMed
  21. Clin Ther. 2015 Apr 1;37(4):764-82 - PubMed

Publication Types